MedTrace Logo

Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations

NCT07354269 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-01-21

No results posted yet for this study

Summary

The goal of this clinical study is to compare the immunogenicity and safety of one dose of sIPV in adolescents or adults aged 7-50 years with that of three doses of DTaP-IPV-Hib Pentavalent Vaccine in Infants Aged 3 Months

Conditions

  • Poliomyelitis

Interventions

BIOLOGICAL

sIPV

one dose of sIPV administered via intramuscular injection

BIOLOGICAL

DTaP-IPV-Hib

three doses of DTaP-IPV-Hib administered via intramuscular injection following the schedule of 3,4,5 months old

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-26
Primary Completion
2026-04-11
Completion
2026-05-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07354269 on ClinicalTrials.gov